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ABSTRACT The resolution of malaria infection is dependent on a balance between
proinﬂammatory and regulatory immune responses. While early effector T cell re-
sponses are required for limiting parasitemia, these responses need to be switched
off by regulatory mechanisms in a timely manner to avoid immune-mediated tissue
damage. Interleukin-10 receptor (IL-10R) signaling is considered to be a vital compo-
nent of regulatory responses, although its role in host resistance to severe immune
pathology during acute malaria infections is not fully understood. In this study, we
have determined the contribution of IL-10R signaling to the regulation of immune
responses during Plasmodium berghei ANKA-induced experimental cerebral malaria
(ECM). We show that antibody-mediated blockade of the IL-10R during P. berghei
ANKA infection in ECM-resistant BALB/c mice leads to ampliﬁed T cell activation,
higher serum gamma interferon (IFN-) concentrations, enhanced intravascular accu-
mulation of both parasitized red blood cells and CD8 T cells to the brain, and an
increased incidence of ECM. Importantly, the pathogenic effects of IL-10R blockade
during P. berghei ANKA infection were reversible by depletion of T cells and neutral-
ization of IFN-. Our ﬁndings underscore the importance of IL-10R signaling in pre-
venting T-cell- and cytokine-mediated pathology during potentially lethal malaria in-
fections.
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The regulation of pathological mechanisms leading to cerebral malaria (CM), a severecomplication of infection with the malaria parasite Plasmodium falciparum, remains
obscure. Experimental CM (ECM) due to Plasmodium berghei ANKA infection in suscep-
tible C57BL/6 mice mimics the neurological signs observed during human CM, includ-
ing ataxia and/or paralysis, which rapidly deteriorate to convulsions, coma, and death
7 to 10 days postinfection (1, 2). Histological examination of both CM and ECM brain
sections reveals the presence of petechial hemorrhages (3–5). Furthermore, both CM
and ECM are characterized by the accumulation of parasitized red blood cells (pRBCs)
and leukocytes in the cerebral microvasculature.
In C57BL/6 mice, the development of ECM is associated with CD8 Clec9A
dendritic cells (DCs), which prime naive CD4 and CD8 T cells to become effector cells
and secrete proinﬂammatory cytokines such as gamma interferon (IFN-) (6, 7). The
production of IFN- by CD4 T cells is thought to enhance the recruitment of effector
CD8 T cells to brain microvessels, where pRBCs also accumulate (8, 9). These effector
CD8 T cells, upon recognition of the parasite-derived epitopes presented by the brain
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endothelial cells (10, 11), secrete perforin and granzymes, leading to breaching of the
blood-brain barrier (12–14) and causing hemorrhages. Besides neurological impair-
ment, P. berghei ANKA-infected C57BL/6 mice develop a multiorgan disease, and in the
absence of cerebral pathology, animals die at a later time point because of anemia and
hyperparasitemia (9).
In contrast, P. berghei ANKA infection of BALB/c mice does not generally lead to ECM
and therefore this strain is considered ECM resistant, although the infected animals
succumb to anemia and hyperparasitemia 2 to 3 weeks postinfection (1, 15). However,
the immune mechanisms that confer resistance to ECM remain poorly understood. We
previously showed that T cell inhibitory pathways, cytotoxic T lymphocyte antigen 4
(CTLA-4, CD152), and programmed death 1 (PD-1, CD279)/PD ligand 1 (PD-L1, CD274)
independently regulate host resistance to ECM (15). Blockade of the CTLA-4 or PD-1/
PD-L1 pathway in P. berghei ANKA-infected BALB/c mice led to the development of ECM
with characteristics similar to those observed in C57BL/6 mice.
Interleukin (IL-10), an anti-inﬂammatory cytokine, is a principal regulator of immu-
nity to infection. IL-10 signaling through its receptor (IL-10R, CD210) is known to
attenuate the production of IFN- and other proinﬂammatory responses (16, 17), which
may otherwise induce immune pathology during acute infections. In the nonlethal
models of P. chabaudi and P. yoelii blood stage malaria infection, deﬁciency in IL-10
signaling is associated with increased IFN- secretion and good parasite control at the
expense of exacerbated immune pathology (18–20). Likewise, IL-10 deﬁciency is fatal in
the avirulent murine models of both Toxoplasma gondii and Trypanosoma cruzi (21, 22).
Together, these studies clearly indicate a critical role for the IL-10R signaling pathway
in preventing pathology. IL-10R signaling attenuates the production of IFN- and other
proinﬂammatory responses responsible for inducing immune-mediated pathology dur-
ing acute parasitic infections.
In the present study, we hypothesized that IL-10R signaling also regulates T-cell-
mediated inﬂammatory responses in ECM-resistant BALB/c mice, thereby preventing
the onset of ECM. Blockade of the IL-10R during P. berghei ANKA infection of BALB/c
mice results in acute immune-mediated pathology with features resembling those of
ECM in susceptible mice. Therefore, the IL-10R signaling pathway appears to effectively
maintain the equilibrium between pathogen clearance and tissue damage during the
early stages of a lethal malaria infection in BALB/c mice.
RESULTS
Blockade of IL-10R signaling induces ECM in normally resistant BALB/c mice. To
establish whether IL-10R signaling regulates ECM pathogenesis in an otherwise ECM-
resistant mouse strain, the outcomes of P. berghei ANKA infection in control mice and
mice treated with blocking antibodies to IL-10R were compared. While control BALB/c
mice (treated with rat IgG or phosphate-buffered saline [PBS]) survived for up to 2
weeks postinfection, mice treated with anti-IL-10R antibody developed classical neu-
rological signs of ECM and were euthanized on day 7 or 8 postinfection (Fig. 1A and B).
Both the survival curve and the cumulative ECM incidence of anti-IL-10R antibody-
treated mice differ signiﬁcantly from those of control mice. Strikingly, anti-IL-10R
antibody-treated mice presented signiﬁcantly lower parasitemia levels on days 5 and 7
postinfection than control mice (Fig. 1C). Consistent with the development of ECM, the
number of accumulated intravascular CD8 T cells was higher in the brains of anti-IL-
10R antibody-treated mice than in those of control mice (Fig. 1D).
A key feature of human CM and ECM in mice is the accumulation of pRBCs in the
brain microvasculature. To determine the effects of IL-10R signaling on parasite accu-
mulation, control and anti-IL-10R antibody-treated mice were infected with P. berghei
ANKA luc parasites that express luciferase. The survival curve and cumulative ECM
incidence (Fig. 2A and B) of P. berghei ANKA luc-infected control and anti-IL-10R
antibody-treated mice were similar to those of P. berghei ANKA-infected mice, although
the onset of ECM was somewhat delayed. Anti-IL-10R antibody-treated P. berghei ANKA
luc-infected mice developed ECM between days 7 and 12 postinfection, and control
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mice survived until day 25. P. berghei ANKA luc-infected anti-IL-10R antibody-treated
mice presented with signiﬁcantly lower parasitemia values on days 5 and 7 postinfec-
tion than control mice (Fig. 2C). However, when parasite accumulation was measured
by luminescence in the whole body (Fig. 2D), head (Fig. 2E), and isolated brain (Fig. 2F
and G), the values were signiﬁcantly higher in anti-IL-10R antibody-treated mice than
in control mice. These results indicate that despite a lighter peripheral parasite burden
in anti-IL-10R antibody-treated mice than in control mice, the generalized parasite
biomass is signiﬁcantly elevated when the IL-10R signaling pathway is blocked.
FIG 2 ECM after IL-10R blockade in P. berghei ANKA-infected BALB/c mice is associated with parasite accumulation
in the brain. BALB/c mice were infected i.v. with 104 P. berghei ANKA luc pRBCs and either left untreated (control)
or treated with anti-IL-10R antibodies. (A) Cumulative survival curve. Closed diamonds (}), control (n  16); open
diamonds (), anti-IL-10R antibody (n  15); ***, P  0.0001 (log rank [Mantel-Cox] test). (B) Cumulative incidence
of mice developing ECM. ***, P  0.0001 (Fisher’s exact test). Similar to Fig. 1, mice that survived were euthanized
because of high levels of parasitemia and anemia. (C) Parasitemia levels, shown as the mean  the standard
deviation, of P. berghei ANKA-infected mice. The data shown are representative of two independent experiments
performed with ﬁve mice per group. *, P 0.05 (Mann-Whitney U test). (D to G) Parasite accumulation in the whole
body (D), head (E), and isolated brain (F, G) as measured by luciferase activity on day 7 postinfection. The data
shown are representative of two independent experiments performed with ﬁve mice per group. In panels D, E, and
G, the data shown are the mean  the standard deviation. *, P  0.05; **, P  0.001 (Mann-Whitney U test).
FIG 1 IL-10R blockade in P. berghei ANKA-infected BALB/c mice results in ECM. BALB/c mice were
infected i.v. with 104 P. berghei ANKA pRBCs and treated with anti-IL-10R antibodies. Control mice
received either no antibody or rat IgG. (A) Cumulative survival curve. Closed circles (), control (n  12);
open circles (Œ), anti-IL-10R antibody (-IL-10R) (n  12). ***, P  0.0001 (log rank [Mantel-Cox] test). (B)
Cumulative incidence of mice developing ECM (based on neurological signs, i.e., ataxia and paralysis). ***,
P  0.0001 (Fisher’s exact test). Mice that survived were euthanized on day 14 because of high
parasitemia and anemia. (C) Parasitemia levels, shown as the mean  the standard deviation, of P.
berghei ANKA-infected mice. Closed circles, control; open circles, anti-IL-10R antibody. The data
shown are representative of three independent experiments with four to six mice per group. *, P 
0.05 (Mann-Whitney U test). (D) Absolute numbers of CD8 T lymphocytes that have accumulated
in the brain. The data shown (mean  standard deviation) are representative of two independent
experiments with four mice per group. *, P  0.05 (Mann-Whitney U test).
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Histological examination of the brains and livers of P. berghei ANKA luc-infected
control and anti-IL-10R antibody-treated mice was also performed. The numbers of
brain petechial hemorrhages were signiﬁcantly higher in anti-IL-10R antibody-treated
mice than in control mice (Fig. 3A, B), while the numbers of microvessels with
leukocytes did not differ between the two groups (Fig. 3C). Moreover, there was also no
difference between the numbers of perivascular inﬁltrates in the liver in the two groups
(Fig. 3E), although there was a trend of ﬁnding necrosis in anti-IL-10R antibody-treated
mice but not in control mice (Fig. 3D and F). Taken together, these ﬁndings signify that
blocking IL-10R signaling in otherwise ECM-resistant mice results in the development of
immune pathology with all of the features of ECM.
Effector responses are ampliﬁed following IL-10R blockade. ECM is a result of
T-cell-mediated inﬂammation in C57BL/6 mice. The development of ECM in P. berghei
ANKA-infected anti-IL-10R antibody-treated BALB/c mice was indicative of an ampliﬁed
inﬂammatory response. As an indicator of systemic inﬂammation, serum IFN- concen-
trations (Fig. 4A) were signiﬁcantly higher in anti-IL-10R antibody-treated mice than in
control and uninfected mice on day 7 postinfection. Consistent with the blockade of
IL-10R signaling, serum IL-10 concentrations (Fig. 4B) were also signiﬁcantly higher in
anti-IL-10R antibody-treated mice than in control and uninfected mice. The levels of
splenic activation were also evaluated on day 6 postinfection. The ﬂow cytometry
gating strategies used are shown in Fig. S1A, B, and F in the supplemental material.
There was a trend toward larger proportions of splenic CD4 and CD8 T cells
expressing CD62L and CD11a and producing IFN- in the anti-IL-10R antibody-
treated mice than in the control and uninfected mice (see Fig. S1B to I). Considering
splenic leukocyte counts, a statistically signiﬁcant difference between the control and
anti-IL-10R antibody-treated groups was reached for the total numbers of CD4 T cells
expressing CD11a, and CD4, and CD8 T cells producing IFN- (Fig. 4C to H). Taken
together, the results show that the development of ECM in P. berghei ANKA-infected
anti-IL-10R antibody-treated BALB/c mice correlates with higher levels of systemic
inﬂammation and T cell activation.
Development of ECM in BALB/c mice following IL-10R blockade is mediated by
T cells and IFN-. The data presented so far indicate that blockade of IL-10R signaling
leads to full ECM susceptibility in otherwise resistant BALB/c mice, and this is associated
with ampliﬁed T cell activation and higher serum IFN- concentrations. These ﬁndings
are consistent with the hypothesis that signaling through the IL-10R switches off
FIG 3 ECM after IL-10R blockade in P. berghei ANKA-infected BALB/c mice is associated with brain pathology. (A)
Histological examination of H&E-stained brain sections from uninfected and day 7 P. berghei ANKA (PbA) luc pRBC-infected
mice (n  7 per group). Asterisks indicate areas of vessels with leukocytes, while circumﬂexes signify hemorrhages.
Magniﬁcation, 20. Graphs show the quantiﬁcation of the number of petechial hemorrhages (B) and vessels with
leukocytes (C). (D) Similar to panel A but with liver sections. Graphs show the scoring of pigmented macrophages (E) and
necrosis (F). In panels B, C, E, and F, the data shown are the mean  the standard deviation. *, P  0.05; ***, P  0.0001
(Mann-Whitney U test).
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T cell reactivity and thus inhibits the development of ECM. To ascertain whether T
cell populations are the targets of IL-10R-mediated regulation, anti-IL-10R antibod-
ies were combined with depletion of antibodies speciﬁc for CD4 or CD8 T cells
in vivo. Depletion of either CD4 or CD8 T cells during P. berghei ANKA luc infection
prevented the development of ECM in anti-IL-10R antibody-treated mice (Fig. 5A and
B). CD4 or CD8 T-cell-depleted mice developed severe anemia and eventually died
2 to 3 weeks postinfection. The role of IFN- in the development of ECM in anti-IL-10R
antibody-treated P. berghei ANKA luc-infected BALB/c mice was also determined by
combination with anti-IFN- neutralizing antibodies throughout infection. Neutraliza-
tion of IFN- during P. berghei ANKA luc infection prevented the development of ECM
in anti-IL-10R antibody-treated mice (Fig. 5A and B). P. berghei ANKA luc-infected
anti-IL-10R antibody-treated mice presented peripheral parasitemia levels similar to
those of mice given anti-CD8, -CD4, or -IFN- antibodies (Fig. 5C). Interestingly,
treatment with anti-CD8, -CD4, or -IFN- antibodies led to signiﬁcantly less parasite
accumulation in the whole bodies (Fig. 5D) and heads of infected animals (Fig. 5E).
These data demonstrated that while the parasite biomass is increased by IL-10R
blockade, the effect is reversed in the absence of T cells or IFN-.
DISCUSSION
Our ﬁndings provide an increased understanding of the regulatory pathways that
impact the outcome of infection with an ECM-inducing rodent malaria strain that
FIG 4 Enhanced effector responses after IL-10R blockade in P. berghei ANKA-infected BALB/c mice. BALB/c mice were infected
i.v. with 104 P. berghei ANKA luc pRBCs (A and B) or 104 P. berghei ANKA pRBCs (C to E) and either left untreated (control) or
treated with anti-IL-10R antibodies. Serum IFN- (A) and IL-10 (B) levels were determined with Quantikine kits from R&D
Systems. For cellular analyses, splenocytes were prepared from uninfected or day 6 infected mice and stained for surface CD3,
CD4, CD8, CD62L, and CD11a. The data shown are gated on CD3 T cells (see Fig. S1). The absolute numbers (mean standard
deviation) of CD4 CD62L cells (C), CD4 CD11a cells (D), CD8 CD62L cells (F), and CD8 CD11a cells (G) are shown.
Splenocytes were also stimulated with PMA/ionomycin for 5 h in the presence of brefeldin A; this was followed by intracellular
IFN- staining. The absolute numbers (mean  standard deviation) of CD4 IFN- cells (E) and CD8 IFN- cells (H) are
shown. The results shown are pooled data from two similar experiments (three to ﬁve mice per group). The data shown are
the mean  the standard deviation. *, P  0.05; **, P  0.001; ***, P  0.0001 (Kruskal-Wallis test/Dunn’s multiple-comparison
test).
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mimics the pathological processes associated with CM due to P. falciparum in humans.
We have shown that blocking IL-10R facilitates the development of acute immune
pathology in normally ECM-resistant BALB/c mice with pathological features compat-
ible with ECM in susceptible C57BL/6 mice. Neuropathological signs were associated
with heavy parasite loads, the development of IFN--secreting CD4 and CD8 T cells
in the spleen, and an inﬂux of CD8 T cells into the brains of IL-10R antibody-treated
mice. Thus, IL-10R signaling plays a vital role in the prevention of immune-mediated
neuropathology during P. berghei ANKA infection of ECM-resistant BALB/c mice.
The outcomes reported in this study expand those reported in our previous work,
where blockade of CTLA-4 or PD-1/PD-L1 inhibitory pathways in P. berghei ANKA-
infected BALB/c mice also rendered the animals susceptible to ECM. Both studies show
that depletion of T cells and neutralization of IFN- abrogated the effects of regulatory
pathway blockade, validating the notion that ECM has similar etiologies in both BALB/c
mice and susceptible C57BL/6 mice. Both studies further corroborate that CD8 T cells
and IFN- are the critical effectors of ECM. While damage to brain vessels has implicated
perforin and granzyme secretion in P. berghei ANKA-infected C57BL/6 mice (12–14), the
roles of these molecules in BALB/c mice warrant further investigation. While it appears
that the CTLA-4, PD-1/PD-L1, and IL-10-R pathways independently regulate host resis-
tance to P. berghei ANKA infection of BALB/c mice, further studies are also needed to
understand the role that the CTLA-4 and/or PD-1/PD-L1 axes are playing in the context
of IL-10R and to identify whether there is a primary regulatory pathway for T cells in this
infection model.
While our depletion experiments suggest that the pathological effects of IL-10R
blockade result from the regulation of T cell responses, additional studies are required
to ascertain the roles of IL-10R expression and IL-10R blockade in other immune cells.
DCs and monocytes have been shown to produce IL-10 during malaria infections
(23–25). Similarly, B cells have also been reported to produce IL-10 in P. berghei
ANKA-infected C57BL/6 mice (26). Recently, tissue-resident CD169 macrophages were
FIG 5 ECM after IL-10R blockade in P. berghei ANKA-infected BALB/c mice is dependent on T cells and
IFN-. BALB/c mice were infected i.v. with 104 P. berghei ANKA luc pRBCs and treated with anti-IL-10R
antibody. (A) Cumulative survival curves of IL-10R blockade alone (e, n  10), with anti-CD8 T cell
depletion (o, n  8), with anti-CD4 T cell depletion (p, n  7), and with anti-IFN- neutralization (,
n 7). P values (log rank [Mantel-Cox] test) are shown. (B) Cumulative incidence of mice developing ECM.
*, P  0.05; **, P  0.001; ***, P  0.0001 (Fisher’s exact test). Similar to Fig. 1 and 2, mice that survived
were euthanized because of high levels of parasitemia and anemia. (C) Parasitemia levels, shown as the
mean  the standard deviation, of P. berghei ANKA luc-infected mice represented by the same symbols
as in panel A. (D, E) Parasite accumulation in the whole body (D) and head (E) as measured by luciferase
activity on day 7 postinfection. The data shown are the mean  the standard deviation. **, P  0.001;
***, P  0.0001 (Kruskal-Wallis test/Dunn’s multiple-comparison test). The data shown are representative
of two independent experiments of at least seven animals per group.
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shown to produce high levels of IL-10 during P. berghei ANKA infection in BALB/c mice
and to restrict inﬂammatory responses (27). Concerning T cells, protection against ECM
may also be due to balanced IFN-/IL-10 secretion in activated T cells versus regulatory
T cells (Tregs). The failure of IL-10 to counterbalance IFN- release during IL-10R
blockade may be attributed to a failure in the IL-10 signaling pathway in both activated
T cells and Tregs with consequent release of IFN-. This assumption on Tregs is backed up
by recent ﬁndings of a loss of FoxP3 expression in Treg cells with increased proinﬂamma-
tory cytokine release during P. chabaudi AS infection in IL-10R-treated DBA/2 mice (28).
Failure of the IL-10R signaling pathway in Tregs has also been associated with loss of
FoxP3 expression and inﬂammatory cytokine release in a murine model of inﬂamma-
tory bowel disease (29, 30). Furthermore, in the murine model of hepatitis C virus
infection, IL-10R blockade steers the inﬂammatory response toward a type 1 IFN--
mediated T cell response (31).
IL-10 production is also increased during P. berghei ANKA infection of ECM-
susceptible C57BL/6 mice (32, 33). It is likely that IL-10 performs a similar regulatory role
in C57BL/6 mice, although its failure to provide protection against ECM remains
unclear. It is possible that an overexuberant inﬂammatory response supersedes the
physiological levels of regulation facilitated by IL-10R signaling. Alternatively, down-
stream IL-10R signaling is impaired on target cells.
Although the kinetics and precise interactions between the effector and regulatory
pathways remain undeﬁned in this model of ECM, our studies reveal the importance of
maintaining a balance between effector and regulatory immune responses for prevent-
ing ECM. Disproportionate proinﬂammatory responses consistently lead to immuno-
pathology, although there is reasonable control of parasitemia. Equally, poor antipa-
rasite immune responses generated concurrently with strong regulatory responses
permit parasitemia with harmful consequences, as demonstrated in this P. berghei
ANKA/BALB/c model of severe malaria.
MATERIALS AND METHODS
Animals. In the United Kingdom, 6- to 12-week-old female BALB/cAnNCrl mice were purchased from
Charles Rivers UK Ltd. and maintained under barrier conditions. Animal experiments were approved by
the London School of Hygiene and Tropical Medicine Animal Welfare and Ethical Review Board and
performed under Animals (Scientiﬁc Procedures) Act 1986. In Singapore, 6- to 7-week-old female BALB/cJ
mice were bred and kept under speciﬁc-pathogen-free conditions in the Biomedical Resource Center of
A*STAR. Animal experiments were approved by the A*STAR Institutional Animal Care and Use Committee
in accordance with the rules and regulations of the Singaporean Agri-Food and Veterinary Authority and
the National Advisory Committee for Laboratory Animal Research.
Parasites and experimental infections. Experimental infections were initiated by intravenous (i.v.)
inoculation of 104 pRBCs. In the United Kingdom, P. berghei ANKA parasites (P. berghei ANKA clone 15cy1
[34], referred to here simply as P. berghei ANKA) expressing green ﬂuorescent protein were used. In
Singapore, transgenic parasite P. berghei ANKA line 231cl1 expressing luciferase and green ﬂuorescent
protein (referred to here as P. berghei ANKA luc) was provided by Christian Engwerda (QIMR Berghofer
Medical Research Institute, Brisbane, Australia). Infected mice were monitored for neurological signs
(uncoordinated and reduced locomotion, paralysis, deviation of the head, ataxia, convulsions, and coma).
Parasitemia levels were monitored by the examination of Giemsa-stained thin blood smears or by ﬂow
cytometry (35). In some experiments, day 7 infected mice were sacriﬁced and perfused and their brains
and livers were removed for histology or imaging (see below). Serum was stored at 70°C for cytokine
quantiﬁcation (see below).
In vivo administration of antibodies. All antibodies were administered by intraperitoneal injection.
Blocking antibody to IL-10R [1B1.3A] was administered at 0.3 mg/mouse on day 1 postinfection and at
0.2 mg/mouse on days 1, 4, and 6 postinfection. Neutralizing antibody to IFN- [XMG1.2] was adminis-
tered at 0.4 mg/mouse on days 4 and 6 postinfection, and depleting antibodies to CD4 [GK1.5] and CD8
[53.6.72] were administered at 1 mg/mouse on day 6 postinfection. All antibodies were rat anti-mouse
IgG, obtained from BioXCell (USA); control rat IgG was obtained from Pierce.
Flow cytometry. The antibodies (clones) used for cell surface staining were (obtained from eBiosci-
ence) anti-mouse CD4 (GK1.5), CD8 (53.6-7), CD11a (M17/4), and CD62L (MEL-14) or (obtained from BD
Biosciences) anti-mouse CD3 (145-2C11), CD4 (RM4-5), and CD8 (53-6.7). Isolated brain and splenic
leukocytes were directly stained in accordance with standard protocols (15). Antibodies used for
intracellular staining were obtained from eBioscience (IFN- [XMG1.2]). Intracellular staining was per-
formed by permeabilizing cells with 0.1% saponin–PBS. Cells were analyzed with a FACSCalibur or LSR
II (BD Immunocytometry Systems) and FlowJo software (TreeStar). Gating strategies were performed as
previously described, where T cells are gated from singlets/live and lymphocyte populations (15).
Absolute numbers of lymphocytes were calculated from cell counts.
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Cytokine quantiﬁcation. Serum cytokine levels were assayed with the IFN- Quantikine kit and the
Quantikine ELISA mouse IL-10 kit (both from R&D Systems) in accordance with the manufacturer’s
protocol. Intracellular IFN- levels were measured by ﬂow cytometry (as described above) following 5 h
of spleen cell culturing in the presence of phorbol myristate acetate (PMA; 50 ng/ml), ionomycin (1
g/ml), and brefeldin A (1 g/ml).
Bioluminescent imaging. Daily in vivo imaging was done to monitor the P. berghei ANKA luc parasite
distribution (IVIS; Xenogen, Alameda, CA). Infected mice were shaved, anesthetized, and injected
subcutaneously with 100 l of D-luciferin potassium salt (5 mg/ml in PBS; Caliper Life Sciences). Two
minutes later, bioluminescence images were acquired with a medium binning factor and a ﬁeld of view
(FOV) of 21.7 cm for the whole body (ventral) or 4 cm for the head (dorsal). The exposure imaging time
was 5 to 60 s. For ex vivo imaging, mice were given a second injection of luciferin and anesthetized and
3 min later perfused and sacriﬁced. Brains were removed and imaged with a 10-cm FOV. To allow
comparisons of images from different days, uninfected mice injected with luciferin were imaged for
background subtraction. Bioluminescence quantiﬁcation was done by using Living Imaging 4.2 software
and expressed in average radiance units (photons per second per square centimeter per steradian).
Histology. Infected mice were sacriﬁced on day 7 postinfection. Mice were perfused with PBS, and
their isolated brains and livers were immersed in 4% formaldehyde and embedded in parafﬁn. Sagittal
sectioning was performed to obtain 5-m-thick brain and liver sections, which were stained with
hematoxylin and eosin (H&E). Slides were acquired on a Metafer4 (MetaSystems), and numbers of
hemorrhages, leukocytes, and necroses (of the liver) were manually determined.
Statistical analysis. Differences in survival were assessed with the log rank (Mantel-Cox) test, and
Bonferroni correction was used to adjust for multiple comparisons within the log rank (Mantel-Cox) test.
The cumulative ECM incidence between two groups was analyzed with Fisher’s exact test. Comparisons
of two groups were made with the Mann-Whitney test, and for multiple comparisons (more than two
groups), statistical signiﬁcance was determined with the Kruskal-Wallis test with Dunn’s posttest. For
log-transformed values to allow normal distribution of the data, analysis of variance with Bonferroni’s
posttest for multiple groups was used. The data were analyzed with GraphPad Prism software (version
6.0) with P  0.05 as the level of signiﬁcance.
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